Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771980 | 0.87 | GAA (0.51) | ALDH1A1LARS1GAAL3MBTL1MEN1 | |
| SCHEMBL2770132 | 0.84 | ABCB1 (0.44) | ALDH1A1PTGDR2GAACYP2C9PTGDR | |
| SCHEMBL2769434 | 0.83 | PTGDR2 (0.41) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL2770449 | 0.72 | ACLY (0.44) | ALDH1A1GAAAKR1C3L3MBTL1MEN1 | |
| SCHEMBL13800545 | 0.71 | HCRTR2 (0.46) | ALDH1A1PTGDR2CYP2C9MEN1KMT2A | |
| SCHEMBL2769298 | 0.69 | PTGDR2 (0.52) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL4635262 | 0.66 | HCRTR1 (0.55) | ALDH1A1PTGDR2HTR6GAACYP2C9 | |
| SCHEMBL3597788 | 0.65 | FBP1 (0.39) | ALDH1A1GAA | |
| SCHEMBL2770472 | 0.65 | EGFR (0.43) | ALDH1A1PTGDR2GAACYP2C9L3MBTL1 | |
| SCHEMBL7774671 | 0.65 | L3MBTL1 (0.61) | ALDH1A1LARS1GAAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1910357-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163534-A1 | Indolizine Derivatives | HRH4, HRH2, NR1H2 | ALDH1A1 3086/4885LARS1 3864/4885PTGDR2 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.